Metabolomics analysis of cervical cancer, cervical intraepithelial neoplasia and chronic cervicitis by 1H NMR spectroscopy

Metabolomics profiles of serum samples from women with chronic cervicitis, cervical intraepithelial neoplasia (CIN), and cervical cancer were characterized by proton nuclear magnetic resonance (1H NMR). These spectral profiles were subjected to partial leastsquares discriminant analysis (PLS-DA), and good discriminations between cancer and non-cancer groups (chronic cervicitis and CIN) were achieved by multivariate modeling of serum profiles. The main metabolites contributing to these discriminations, as highlighted by multivariate analysis and confirmed by spectral integration, were formate, tyrosine, β-glucose, inositol, glycine, carnitine, glutamine, acetate, alanine, valine, isoleucine, and very-low-density lipoprotein (VLDL). Metabolomics analysis for chronic cervicitis, CIN, and cervical cancer is significant, which give a systemic metabolic response of these female diseases. The systemic metabolic response may be used to identify the potential biomarkers for the diseases.

Metabolomics; Cervical cancer; Cervical intraepithelial neoplasia; Chronic Cervicitis; 1H NMR spectroscopy; PLS-DA.

[1] Yang B.H., Bray F.I., Parkin D.M., Sellors J.W., Zhang Z.F.: “Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost”. Int. J. Cancer, 2004, 109, 418.

[2] Arbyn M., Castellsague X., de Sanjose S., Bruni L., Saraiya M., Bray F., et al.: “Worldwide burden of cervical cancer in 2008”. Ann. Oncol., 2011, 22, 2675.

[3] Soerjomataram I., Lortet-Tieulent J., Parkin D.M., Ferlay J., Mathers C., Forman D., et al.: “Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions”. Lancet, 2012, 380, 1840. doi: 10.1016/S0140-6736(12) 60919-2.

[4] Bray F., Jemal A., Grey N., Ferlay J., Forman D.: “Global cancer transitions according to the human development index (2008-2030): a population-based study”. Lancet Oncol., 2012, 13, 790.

[5] Chen D., Juko-Pecirep I., Hammer J., Ivansson E., Enroth S., Gustavsson I., et al.: “Genome-wide association study of susceptibility loci for cervical cancer”. J. Natl. Cancer Inst., 2013, 105, 624.

[6] Schiffman M., Castle P.E.: “Human papillomavirus: epidemiology and public health”. Arch. Pathol. Lab. Med., 2003, 127, 930.

[7] Kinde I., Bettegowda C.,Wang Y.X.,Wu J., Agrawal N., Shih I.M., et al.: “Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers”. Sci. Transl. Med., 2013, 5, 167ra4. doi: 10.1126/scitranslmed.3004952.

[8] Guo M, Gong Y, Wang JP, Dawlett M, Patel S, Liu P, et al. The role of human papillomavirus type 16/18 genotyping in predicting highgrade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal papanicolaou results. Cancer Cytopathol., 2013, 121, 2, 79.

[9] Abulafia O., Pezzullo J.C., Sherer D.M.: “Performance of thinPrep liquid-based cervical cytology in comparison with conventionally prepared papanicolaou smears: a quantitative survey”. Gynecol. Oncol., 2003, 90, 137.

[10] Monsonego J., Autillo-Touati A., Bergeron C., Dachez R., Liaras J., Saurel J., et al.: “Liquid-based cytology for primary cervical cancer screening: a multi-centre study”. Brit. J. Cancer, 2001, 84, 360.

[11] Doyle B., O’Farrell C., Mahoney E., Turner L., Magee D., Gibbons D.: “Liquid-based cytology improves productivity in cervical cytology screening”. Cytopathology, 2006, 17, 60.

[12] Whynes D.K., Sharp L., Cotton S.C., Cruickshank M., Gray N.M., Little J., et al.: “Impact of alternative management policies on healthrelated quality of life in women with low-grade abnormal cervical cytology referred for colposcopy”. Eur. J. Obstet. Gyn. Reprod Biol., 2013, 169, 88.

[13] Monsonego J., Hudgens M.G., Zerat L., Zerat J.C., Syrjanen K., Smith J.S.: “Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study)”. Gynecol. Oncol., 2012, 125, 175.

[14] Sigurdsson K.: “Is a liquid-based cytology more sensitive than a conventional pap smear?” Cytopathology, 2013, 24, 254.

[15] Ye N.S., Li J.: “Serum protein profiling of cervical cancer patients using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry”. Anal. Lett., 2013, 46, 250.

[16] Putri S.P., NakayamaY.,Matsuda F., Uchikata T., Kobayashi S., Matsubara A., et al.: “Current metabolomics: practical applications”. J. Biosci. Bioeng., 2013, 115, 579.

[17] Monteiro M.S., Carvalho M., Bastos M.L., de Pinho P.G.: “Metabolomics analysis for biomarker discovery: advances and challenges”. Curr. Med. Chem., 2013, 20, 257.

[18] Fan L.J., Zhang W., Yin M.Z., Zhang T., Wu X.Y., Zhang H.Y., et al.: “Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform”. Acta Oncol., 2012, 51, 473.

[19] Jankevics A., Liepinsh E., Liepinsh E., Vilskersts R., Grinberga S., Pugovics O., et al.: “Metabolomic studies of experimental diabetic urine samples by 1H NMR spectroscopy and LC/MS method”. Chemometr. Intell. Lab., 2009, 97, 11.

[20] Grivet J.P., Delort A.M., Portais J.C.: “NMR and microbiology: from physiology to metabolomics”. Biochimie, 2003, 85, 823.

[21] Beckonert O., Keun H.C., Ebbels T.M.D., Bundy J.G., Holmes E., Lindon J.C., et al.: “Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts”. Nat. Protoc., 2007, 2, 2692.

[22] Emwas A.H.M., Salek R.M., Griffin J.L., Merzaban J.: “NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations”. Metabolomics, 2013, 9, 1048. doi: 10.1007/ s11306-013-0524-y

[23] Odunsi K., Wollman R.M., Ambrosone C.B., Hutson A., McCann S.E., Tammela J., et al.: “Detection of epithelial ovarian cancer using 1H NMR-based metabonomics”. Int. J. Cancer, 2005, 113, 782.

[24] Tiziani S., Lopes V., Gunther U.L.: “Early stage diagnosis of oral cancer using 1H NMR-based metabolomics”. Neoplasia, 2009, 11, 269.

[25] Ronco G., Segnan N., Giorgi-Rossi P., Zappa M., Casadei G.P., Carozzi F., et al.: “Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial”. J. Natl. Cancer Inst., 2006, 98, 765.

[26] Ronco G., Cuzick J., Pierotti P., Cariaggi M.P., Dalla Palma P., Naldoni C., et al.: “Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomised controlled trial”. BMJ, 2007, 335, 28.

[27] Lyng H., Sundfor K., Rofstad E.K.: “Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis”. Int. J. Radiat. Oncol., 2000, 46, 935.

[28] Lyng H., Sundfor K., Trope C., Rofstad E.K.: “Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy”. Clin. Cancer Res., 2000, 6, 1104.

[29] Mahon M.M., deSouza N.M., Dina R., SoutterW.P., McIndoe G.A., Williams A.D., et al.: “Preinvasive and invasive cervical cancer: an ex vivo proton magic angle spinning magnetic resonance spectroscopy study”. NMR Biomed., 2004, 17, 144.

[30] Sitter B., Bathen T., Hagen B., Arentz C., Skjeldestad F.E., Gribbestad I.S.: “Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy”. MAGMA, 2004, 16, 174.

[31] Daly P.F., Lyon R.C., Faustino P.J., Cohen J.S.: “Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy”. J. Biol. Chem.,1987, 262, 14875.

[32] Rocha C.M., Carrola J., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., et al.: “Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma”. J. Proteome. Res., 2011, 10, 4314.

[33] Carrola J., Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., et al.: “Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine”. J. Proteome. Res., 2011, 10, 221.

[34] Wei L., Liao P.Q.,Wu H.F., Li X.J., Pei F.K., LiW.S., et al.: “Toxicological effects of cinnabar in rats by NMR-based metabolic profiling of urine and serum”. Toxicol. Appl. Pharm., 2008, 227, 417.

[35] Hasim A., Ali M., Mamtimin B., Ma J.Q., Li Q.Z., Abudula A.: “Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by 1H NMR spectroscopy”. Exp. Ther. Med., 2012, 3, 945.

[36] Carraro P., Zago T., Plebani M.: “Exploring the initial steps of the testing process: frequency and nature of pre-preanalytic errors”. Clin. Chem., 2012, 58, 638.

[37] Yin P.Y., Peter A., Franken H., Zhao X.J., Neukamm S.S., Rosenbaum L., et al.: “Preanalytical aspects and sample quality assessment in metabolomics studies of human blood”. Clin. Chem., 2013, 59, 833.

[38] Leray G., Quemener V., Rumeur E.L., Benoist L., Auvray E., Decertaines J.D.: “Proton NMR spectroscopy of plasma lipoproteins in the experimental Lewis lung carcinoma”. Anticancer Res., 1992, 12, 1227.